Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 193

Results For "clinical"

2937 News Found

We must be careful in adopting global technological practices, says Union Health Secretary
Digitisation | August 13, 2022

We must be careful in adopting global technological practices, says Union Health Secretary

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces


Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr
News | August 12, 2022

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.


AI to shape future outcomes in cardiovascular care, says GlobalData
Digitisation | August 11, 2022

AI to shape future outcomes in cardiovascular care, says GlobalData

AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.


HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer
Clinical Trials | August 09, 2022

HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer

Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.


Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
Clinical Trials | August 04, 2022

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.


LYNPARZA approved in the EU as adjuvant treatment for early breast cancer
Drug Approval | August 04, 2022

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients


Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes
News | August 02, 2022

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.


Health Minister Mandaviya addresses inaugural ceremony of training programme for senior administrative medical officers of CGHS
Policy | August 02, 2022

Health Minister Mandaviya addresses inaugural ceremony of training programme for senior administrative medical officers of CGHS

Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar


UBC acquires Examoto
Biotech | August 02, 2022

UBC acquires Examoto

With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry